IN2014DN06989A - - Google Patents

Info

Publication number
IN2014DN06989A
IN2014DN06989A IN6989DEN2014A IN2014DN06989A IN 2014DN06989 A IN2014DN06989 A IN 2014DN06989A IN 6989DEN2014 A IN6989DEN2014 A IN 6989DEN2014A IN 2014DN06989 A IN2014DN06989 A IN 2014DN06989A
Authority
IN
India
Prior art keywords
eosinophilic
alkyl
macular degeneration
related macular
age related
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2014DN06989A publication Critical patent/IN2014DN06989A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Structure Of Transmissions (AREA)
IN6989DEN2014 2012-04-03 2013-04-02 IN2014DN06989A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06989A true IN2014DN06989A (enExample) 2015-04-10

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6989DEN2014 IN2014DN06989A (enExample) 2012-04-03 2013-04-02

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP3763369B1 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20140144200A (enExample)
CN (2) CN110384699A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6684363B2 (ja) 2016-11-24 2020-04-22 キリシマ精工株式会社 歯列矯正具
ES3046717T3 (en) * 2017-04-05 2025-12-02 Alkahest Inc Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
EP3606525B1 (en) 2017-04-05 2025-12-10 Alkahest, Inc. Compositions for treating aging-associated impairments using ccr3-inhibitors
CN111343983A (zh) * 2017-10-13 2020-06-26 万能溶剂有限公司 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
BR112020023001A2 (pt) 2018-05-15 2021-02-02 Alkahest, Inc. tratamento de doença associada ao envelhecimento com moduladores da leucotrieno a4 hidrolase
JP7528065B2 (ja) * 2018-09-26 2024-08-05 アルカヘスト,インコーポレイテッド Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
CA3180401A1 (en) * 2020-06-11 2021-12-16 Bartosz SIKORSKI Methods of improving retina-associated disease outcome using ccr3-inhibitors
EP4426284A4 (en) 2021-11-01 2025-11-12 Alkahest Inc Benzodioxane Leukotriene A4 Hydrolase (LTA4H) Modulators for the Prevention and Treatment of Age-Related Diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
EP1259615B1 (en) * 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
EP2833884B1 (en) 2020-05-20
JP2015512432A (ja) 2015-04-27
PL2833884T3 (pl) 2020-11-02
BR112014023795A8 (pt) 2017-10-10
KR20250133980A (ko) 2025-09-09
DK2833884T3 (da) 2020-08-10
US20130261153A1 (en) 2013-10-03
BR112014023795B1 (pt) 2021-09-08
HRP20201165T1 (hr) 2020-12-11
CN110384699A (zh) 2019-10-29
EP2833884A1 (en) 2015-02-11
EP3763369A1 (en) 2021-01-13
EP4389217A2 (en) 2024-06-26
AU2013245027B2 (en) 2017-10-12
NZ628882A (en) 2016-05-27
CY1123222T1 (el) 2021-10-29
HUE051648T2 (hu) 2021-03-29
EA032263B1 (ru) 2019-05-31
KR20200044988A (ko) 2020-04-29
ES2811554T3 (es) 2021-03-12
EA201401083A1 (ru) 2015-03-31
LT2833884T (lt) 2020-09-10
JP2018080183A (ja) 2018-05-24
CL2014002523A1 (es) 2015-01-23
CA2869269C (en) 2020-06-30
ZA201406082B (en) 2019-01-30
US20160081998A1 (en) 2016-03-24
ES2987267T3 (es) 2024-11-14
US20150099783A1 (en) 2015-04-09
CN104220073A (zh) 2014-12-17
AU2013245027A1 (en) 2014-09-11
KR20210063481A (ko) 2021-06-01
RS60665B1 (sr) 2020-09-30
EP4389217A3 (en) 2024-08-28
MX2014011786A (es) 2014-12-05
WO2013149986A1 (en) 2013-10-10
KR20220132012A (ko) 2022-09-29
PH12014502239A1 (en) 2014-12-15
BR112014023795A2 (enExample) 2017-06-20
SMT202000499T1 (it) 2020-11-10
US20170319567A1 (en) 2017-11-09
EP3763369B1 (en) 2024-02-28
SI2833884T1 (sl) 2020-10-30
KR20140144200A (ko) 2014-12-18
PT2833884T (pt) 2020-08-26
CA2869269A1 (en) 2013-10-10
US20200375971A1 (en) 2020-12-03
IL234262A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12014502239A1 (en) Use of ccr3-inhibitors
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
AR099489A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201590581A1 (ru) Соединения бис-(фторалкил)-1,4-бензодиазепинона и их пролекарства
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
EA201290952A1 (ru) Химические соединения
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
BR112014009717A8 (pt) derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.
TN2014000210A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina
MX339759B (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
IN2014DN07082A (enExample)
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare